Non Alcoholic Steatohepatitis Nash Biomarkers Market: Market Size & Forecast 2026

The NASH biomarkers market comprises products and services that detect, stage, and monitor non-alcoholic steatohepatitis, a progressive liver condition affecting a growing share of the global population. Market size estimates for 2025 range from approximately $1.5 billion to $2.0 billion across major industry analyses, with a consensus projection toward $5.7 billion by 2030. The broader NASH therapeutics and diagnostics market is estimated at roughly $5.8 billion in 2025, with diagnostic components accounting for the majority share, reflecting the critical role biomarkers play in disease management.

• •Market size in 2025 is estimated between $1.5 billion and $2.0 billion depending on the methodology used
• •CAGR projections range from approximately 23% to 26% through 2030, with most sources converging near 24%
• •The broader NASH market encompassing both therapies and diagnostics is valued at roughly $5.8 billion in 2025

Rising global prevalence of obesity, type 2 diabetes, and metabolic syndrome has significantly expanded the population at risk for NASH, creating substantial demand for improved diagnostic tools. Historically, liver biopsy has been the gold standard for diagnosis, but its invasive nature, sampling variability, and cost have driven intense interest in blood-based biomarkers, imaging techniques, and algorithmic scoring systems. The anticipated approval of pharmaceutical treatments for NASH is expected to accelerate biomarker adoption, as effective therapies will require precise patient stratification and ongoing disease monitoring.

• •No official government statistical agency publishes a dedicated market-size figure for this segment; all estimates come from private market intelligence firms
• •The NASH disease burden is tracked broadly by agencies such as the WHO and NIH, but commercial market data is independently compiled
• •Advancements in proteomics, metabolomics, and artificial intelligence are expanding the range of clinically viable biomarker candidates

The market is typically segmented by biomarker type into diagnostic, prognostic, and predictive categories, as well as by technology into serum-based assays, imaging biomarkers, genetic markers, and composite algorithmic scores. North America currently holds the largest market share, supported by high disease prevalence, advanced healthcare infrastructure, and strong pharmaceutical R&D investment. The Asia-Pacific region is expected to grow at the fastest pace, driven by rising obesity and diabetes rates alongside improving diagnostic capabilities in emerging economies.

• •Serum biomarkers and non-invasive scoring algorithms represent the most actively developed segments
• •North America leads in market share, while Asia-Pacific is forecast as the fastest-growing regional market
• •Diagnostics components make up roughly 60% of the broader NASH therapeutics and diagnostics market

What are the recent trends and outlook?

A significant industry-wide trend is the transition in nomenclature from NASH to MASH, reflecting updated clinical guidelines, which is influencing drug development and biomarker standardization efforts. There is growing emphasis on non-invasive diagnostic approaches that can reliably replace liver biopsy for disease staging and treatment-response monitoring. Emerging technologies leveraging multi-omics, liquid biopsy, and artificial intelligence are expected to improve the accuracy and accessibility of NASH biomarkers over the forecast period.

• •The global NASH/MASH treatment market is projected to reach approximately $8.1 billion in 2025, with one analysis estimating the total addressable NASH market could grow by over $40 billion through 2030
• •A shift toward the term MASH is reshaping clinical trial endpoints, regulatory pathways, and diagnostic nomenclature
• •Advances in non-invasive biomarker panels and AI-driven diagnostic algorithms are expected to drive the next phase of market expansion